- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.12.24 | BIOSERGEN AB: Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial | 4 | Cision News | ||
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 05.12.24 | BIOSERGEN AB: Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3 | 2 | Cision News | ||
| 03.12.24 | Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3 | 1 | Cision News | ||
| 03.12.24 | Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3 | 1 | Cision News | ||
| 26.11.24 | BIOSERGEN AB: Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections | 1 | Cision News | ||
| 26.11.24 | The last day of trading with the warrants of series TO3 in Biosergen AB is today, November 26, 2024 | 1 | Cision News | ||
| 21.11.24 | BIOSERGEN AB: Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005 | 1 | Cision News | ||
| 18.11.24 | BIOSERGEN AB: Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million | 1 | Cision News | ||
| 18.11.24 | The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49 | 1 | Cision News | ||
| 13.11.24 | BIOSERGEN AB: Biosergen discusses positive results in patients with deadly fungal infections | 2 | Cision News | ||
| 08.11.24 | Biosergen AB: Biosergen publishes interim report for third quarter 2024 | 75 | GlobeNewswire (Europe) | Friday November 8, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the... ► Artikel lesen | |
| 07.11.24 | BIOSERGEN AB: Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial | 1 | Cision News | ||
| 06.11.24 | BIOSERGEN AB: Biosergen's CEO: "I'm optimistic that we may cure patients" | 2 | Cision News | ||
| 31.10.24 | BIOSERGEN AB: Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections | 1 | Cision News | ||
| 18.10.24 | BIOSERGEN AB: Biosergen advances BSG005 antifungal drug candidate trial | 1 | Cision News | ||
| 07.10.24 | Biosergen AB: Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial | 100 | GlobeNewswire (Europe) | October 7, 2024 - Biosergen AB ("Biosergen"), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first... ► Artikel lesen | |
| 06.09.24 | BIOSERGEN AB: Biosergen's CEO: "The first patient regained his health" | 1 | Cision News | ||
| 05.09.24 | Biosergen - Optimism after treatment success - Mangold Insight Analysis | 1 | Cision News | ||
| 30.08.24 | Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005 | 2 | GlobeNewswire (USA) | ||
| 30.08.24 | BIOSERGEN AB: Biosergen publishes interim report for second quarter 2024 | 1 | Cision News |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 54,81 | +8,58 % | Opening Bell: Netflix, Oracle, Procter & Gamble, ARM Holdings, Tempus AI, Constellation Energy | Nach dem Feiertag am Montag startete die Wall Street gestern äußerst freundlich in die Handelswoche. Der Dow Jones legte um 1,24 Prozent zu. Der S&P 500 verbuchte ein Plus von fast 0,9 Prozent und der... ► Artikel lesen | |
| QIAGEN | 44,560 | -3,20 % | DAX-Check LIVE: Munich Re, Qiagen, Rheinmetall, Siemens Energy, SUSS, Zalando im Fokus | Bereits kurz nach Handelsstart markierte der DAX gestern mal wieder ein neues Allzeithoch. Und dieses hatte dann auch bis zum Ende des Tages bestand. Es liegt bei 20.675 Punkten. 20 Zähler darunter... ► Artikel lesen | |
| DOGWOOD THERAPEUTICS | 13,160 | +362,57 % | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 | ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,580 | +0,61 % | Peering Into ADMA Biologics' Recent Short Interest | ||
| AVIDITY BIOSCIENCES | 30,130 | -2,30 % | Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) | ||
| IMMUNOVANT | 23,400 | +0,86 % | Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential | ||
| DYNE THERAPEUTICS | 13,690 | -2,98 % | Dyne's Myotonic Secures FDA's Fast Track Designation For Myotonic Dystrophy Type 1 Therapy | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for DYNE-101 for the treatment of myotonic... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 49,120 | +2,18 % | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen | |
| DISC MEDICINE | 57,06 | -2,59 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,520 | +0,40 % | Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday | ||
| BIONTECH | 117,00 | +5,69 % | Evotec, Vidac Pharma, BioNTech - Geld verdienen mit dem Kampf gegen Krebs | Nicht erst seitdem König Charles und Prinzessin Kate ihre Krebsleiden öffentlich gemacht haben ist klar, dass die Krankheit jeden treffen kann. Der Markt wächst und schon heute gehen die Umsätze in... ► Artikel lesen | |
| ONCO-INNOVATIONS | 1,490 | +23,14 % | Lizenzierte Technologie von Onco-Innovations verhindert in Studie erfolgreich die Regeneration von Krebszellen | Vancouver, Kanada - 16. Januar 2025 / IRW-Press / Onco-Innovations Limited (CSE: ONCO) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich, Informationen über seine exklusiv
lizenzierte... ► Artikel lesen | |
| EVOTEC | 7,910 | -1,12 % | Evotec-Aktie leicht im Minus (7,725 €) | Am deutschen Aktienmarkt notiert die Aktie von Evotec zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 7,73 Euro. Für Inhaber von Evotec ist der heutige Handelstag bisher nicht... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 5,610 | +61,21 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| JANUX THERAPEUTICS | 44,620 | +10,86 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen |
Das Unternehmen BIOSERGEN AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,040 Euro und damit -2,91 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.
